FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
Posted:
The Food and Drug Administration expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
At GIANT Health Event #GIANT2025, Rajesh Sivaprakasam, Lead for Robotic Renal Failure Surgery at Barts Health NHS Trust, shared powerful insights in an interview with EMJ on how operating theatres have evolved over the last decade.
He highlighted a major…
At GIANT Health 2025, Hassan Chaudhury HonFAPM chaired the Innovating NHS Systems Congress, leading vital discussions on how innovation can truly deliver impact across healthcare.
In his EMJ interview, Hassan shared a clear perspective on innovation — highlighting that it…
Attendees
Sponsors and Exhibitors
Contact us